Bio-Path Holdings Inc. (BPTH) Announces Earnings Results
Bio-Path Holdings Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Thursday. The company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02).
Bio-Path Holdings (NASDAQ:BPTH) opened at 1.24 on Friday. Bio-Path Holdings has a one year low of $0.95 and a one year high of $3.19. The firm’s market capitalization is $118.60 million. The stock’s 50 day moving average is $1.18 and its 200-day moving average is $1.79.
Several large investors have recently made changes to their positions in BPTH. BlackRock Investment Management LLC boosted its stake in shares of Bio-Path Holdings by 0.3% in the third quarter. BlackRock Investment Management LLC now owns 308,832 shares of the company’s stock worth $432,000 after buying an additional 817 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Bio-Path Holdings by 5.9% in the third quarter. Bank of New York Mellon Corp now owns 300,426 shares of the company’s stock worth $420,000 after buying an additional 16,679 shares during the period. KCG Holdings Inc. boosted its stake in shares of Bio-Path Holdings by 79.7% in the second quarter. KCG Holdings Inc. now owns 55,118 shares of the company’s stock worth $110,000 after buying an additional 24,450 shares during the period. State Street Corp boosted its stake in shares of Bio-Path Holdings by 2,060.9% in the second quarter. State Street Corp now owns 1,002,676 shares of the company’s stock worth $1,995,000 after buying an additional 956,276 shares during the period. Finally, Rhumbline Advisers acquired a new stake in shares of Bio-Path Holdings during the second quarter worth about $140,000. 18.88% of the stock is owned by institutional investors.
A number of equities research analysts have commented on the stock. Maxim Group reduced their price target on shares of Bio-Path Holdings from $5.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Rodman & Renshaw set a $5.00 price target on shares of Bio-Path Holdings and gave the stock a “buy” rating in a report on Thursday, August 11th.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Stock Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related stocks with our FREE daily email newsletter.